ly 353381 has been researched along with Experimental Mammary Neoplasms in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Farris, MR; Glasebrook, AL; Grese, TA; Heyman, RA; Lamph, WW; Palkowitz, AD; Risingsong, R; Sporn, MB; Suh, N; Williams, CR | 1 |
| Berchuck, A; Heyman, RA; Krajewski, S; Lamph, WW; Liby, K; Reed, JC; Rendi, MH; Risingsong, R; Royce, DB; Sporn, MB; Suh, N; Williams, CR | 1 |
| Tannock, IF; Wu, L | 1 |
| Brown, P; Kim, H; Krajewski, S; Labrie, F; Lamph, W; Liby, K; Rendi, M; Risingsong, R; Royce, DB; Sporn, MB; Suh, N; Williams, CR; Xu, X | 1 |
| Bryant, HU; Burris, LL; Glasebrook, AL; Palkowitz, AD; Pearce, HL; Peer, C; Sporn, MB; Starling, JJ; Suh, N; Wang, Y; Williams, C | 1 |
5 other study(ies) available for ly 353381 and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268.
Topics: Animals; Anticarcinogenic Agents; Cells, Cultured; Drug Synergism; Drug Therapy, Combination; Female; Humans; Mammary Neoplasms, Experimental; Methylnitrosourea; Neoplasm Invasiveness; Nicotinic Acids; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Piperidines; Rats; Selective Estrogen Receptor Modulators; Stromal Cells; Tetrahydronaphthalenes; Thiophenes; Transforming Growth Factor beta | 2002 |
The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Drug Synergism; Mammary Neoplasms, Experimental; NF-kappa B; Nicotinic Acids; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Thiophenes; Transfection; Transforming Growth Factor beta | 2004 |
Effect of the selective estrogen receptor modulator arzoxifene on repopulation of hormone-responsive breast cancer xenografts between courses of chemotherapy.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Bromodeoxyuridine; Cell Line, Tumor; Cell Proliferation; Female; Humans; Immunohistochemistry; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Piperidines; Receptors, Estrogen; Thiophenes; Treatment Outcome; Xenograft Model Antitumor Assays | 2005 |
The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer.
Topics: Animals; Cell Division; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Nicotinic Acids; Piperidines; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Survival Rate; Tetrahydronaphthalenes; Thiophenes | 2006 |
Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer.
Topics: Animals; Anticarcinogenic Agents; Binding, Competitive; Cell Division; Drug Interactions; Estradiol; Estradiol Congeners; Estrogen Antagonists; Ethinyl Estradiol; Female; Humans; Mammary Neoplasms, Experimental; Piperidines; Rats; Receptors, Estrogen; Tamoxifen; Thiophenes; Tumor Cells, Cultured; Uterus | 2001 |